Movement Alert｜INNOCARE Rises 8.12% in Regular Trading, Dual-Antibody ADC ICP-B381 Approved for Clinical Trials

Market Focus09-14

On September 14, INNOCARE rose 8.12% in regular trading, trading at HKD 14.64/share, with turnover of approximately HKD 39.6 million. The rally was driven by the announcement that the company's independently developed dual-antibody ADC drug ICP-B381, targeting PSMA and STEAP1, received approval from China's National Medical Products Administration to commence clinical trials for the treatment of prostate cancer and other solid tumors.

ICP-B381 is the first dual-antibody ADC developed on INNOCARE's proprietary ADC platform, composed of a humanized anti-PSMA/STEAP1 antibody conjugated with the company's next-generation irreversible linker and a potent payload. Notably, at equivalent dosing levels, ICP-B381 demonstrated superior efficacy compared to corresponding single-target PSMA ADC and STEAP1 ADC candidates, while maintaining a favorable tolerability profile. Currently, no dual-antibody ADC targeting both PSMA and STEAP1 has been approved globally, positioning ICP-B381 as a potentially first-in-class therapy.

The broader Hong Kong-listed biotechnology sector also traded higher during the session, with AKESO up 5.09%, 3SBIO up 3.82%, INNOVENT BIO up 1.66%, BEONE MEDICINES up 1.55%, and IMPACT THERAP-B up 1.55%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170267105?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 10:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170267105","market":"hk","top_or_hot":-1,"title":"Movement Alert｜INNOCARE Rises 8.12% in Regular Trading, Dual-Antibody ADC ICP-B381 Approved for Clinical Trials","media":"Market Focus","content":"<p><p>On September 14, INNOCARE rose 8.12% in regular trading, trading at HKD 14.64/share, with turnover of approximately HKD 39.6 million. The rally was driven by the announcement that the company's independently developed dual-antibody ADC drug ICP-B381, targeting PSMA and STEAP1, received approval from China's National Medical Products Administration to commence clinical trials for the treatment of prostate cancer and other solid tumors.</p><p>ICP-B381 is the first dual-antibody ADC developed on INNOCARE's proprietary ADC platform, composed of a humanized anti-PSMA/STEAP1 antibody conjugated with the company's next-generation irreversible linker and a potent payload. Notably, at equivalent dosing levels, ICP-B381 demonstrated superior efficacy compared to corresponding single-target PSMA ADC and STEAP1 ADC candidates, while maintaining a favorable tolerability profile. Currently, no dual-antibody ADC targeting both PSMA and STEAP1 has been approved globally, positioning ICP-B381 as a potentially first-in-class therapy.</p><p>The broader Hong Kong-listed biotechnology sector also traded higher during the session, with AKESO up 5.09%, 3SBIO up 3.82%, INNOVENT BIO up 1.66%, BEONE MEDICINES up 1.55%, and IMPACT THERAP-B up 1.55%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INNOCARE Rises 8.12% in Regular Trading, Dual-Antibody ADC ICP-B381 Approved for Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INNOCARE Rises 8.12% in Regular Trading, Dual-Antibody ADC ICP-B381 Approved for Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-14 10:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 14, INNOCARE rose 8.12% in regular trading, trading at HKD 14.64/share, with turnover of approximately HKD 39.6 million. The rally was driven by the announcement that the company's independently developed dual-antibody ADC drug ICP-B381, targeting PSMA and STEAP1, received approval from China's National Medical Products Administration to commence clinical trials for the treatment of prostate cancer and other solid tumors.</p><p>ICP-B381 is the first dual-antibody ADC developed on INNOCARE's proprietary ADC platform, composed of a humanized anti-PSMA/STEAP1 antibody conjugated with the company's next-generation irreversible linker and a potent payload. Notably, at equivalent dosing levels, ICP-B381 demonstrated superior efficacy compared to corresponding single-target PSMA ADC and STEAP1 ADC candidates, while maintaining a favorable tolerability profile. Currently, no dual-antibody ADC targeting both PSMA and STEAP1 has been approved globally, positioning ICP-B381 as a potentially first-in-class therapy.</p><p>The broader Hong Kong-listed biotechnology sector also traded higher during the session, with AKESO up 5.09%, 3SBIO up 3.82%, INNOVENT BIO up 1.66%, BEONE MEDICINES up 1.55%, and IMPACT THERAP-B up 1.55%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09969","symbol_name":"诺诚健华","start_time":0,"source_url":"","article_id":"1170267105","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170267105","pubTimestamp":1789353665,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 14, INNOCARE rose 8.12% in regular trading, trading at HKD 14.64/share, with turnover of approximately HKD 39.6 million. The rally was driven by the announcement that the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09969":"诺诚健华"},"translate_title":"异动提醒|诺诚健华常规交易大涨8.12%，双抗体ADC ICP-B381获批临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09969":1},"content_text":"On September 14, INNOCARE rose 8.12% in regular trading, trading at HKD 14.64/share, with turnover of approximately HKD 39.6 million. The rally was driven by the announcement that the company's independently developed dual-antibody ADC drug ICP-B381, targeting PSMA and STEAP1, received approval from China's National Medical Products Administration to commence clinical trials for the treatment of prostate cancer and other solid tumors.ICP-B381 is the first dual-antibody ADC developed on INNOCARE's proprietary ADC platform, composed of a humanized anti-PSMA/STEAP1 antibody conjugated with the company's next-generation irreversible linker and a potent payload. Notably, at equivalent dosing levels, ICP-B381 demonstrated superior efficacy compared to corresponding single-target PSMA ADC and STEAP1 ADC candidates, while maintaining a favorable tolerability profile. Currently, no dual-antibody ADC targeting both PSMA and STEAP1 has been approved globally, positioning ICP-B381 as a potentially first-in-class therapy.The broader Hong Kong-listed biotechnology sector also traded higher during the session, with AKESO up 5.09%, 3SBIO up 3.82%, INNOVENT BIO up 1.66%, BEONE MEDICINES up 1.55%, and IMPACT THERAP-B up 1.55%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170267105","isCrawlerRequest":true}